Fumiharu Ohka

14PUBLICATIONS
51CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsTraditional Chinese medicine and treatmentsGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 18, 2026
A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).

|May 19, 2026
Efficacy and safety of multimodality therapy stratified by resection rate and molecular markers in children and adolescents with ependymoma: JCCG EPN23 protocol.

|Apr 15, 2026
On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastoma.

|Mar 12, 2026
Recurrent Mutations in Protein Tyrosine Phosphatase Receptor Type Kappa (PTPRK) in Depressed-Type Colorectal Carcinomas.

Masayuki Tojo, Keiko Shinjo, Fumiharu Ohka

|Dec 31, 2025
Relation between tumor treating fields usage rate ≥75% for the first 3 months and progression-free survival in patients with newly diagnosed WHO grade 4 gliomas.

Shoichi Deguchi, Masashi Kinoshita, Fumiharu Ohka

|Aug 25, 2025
Rapid intraoperative genetic analysis of adult-type diffuse gliomas using a microfluidic real-time polymerase chain reaction device.

Sachi Maeda, Yotaro Kitano, Fumiharu Ohka

Pageof 3

Frequent Collaborators

5 joint publications

Ryuta Saito

4 joint publications

Keiko Shinjo

2 joint publications

Junya Yamaguchi

2 joint publications

Yutaka Kondo